LuÃ-s Carlos Crocco Afonso

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8377287/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The Ecto-5 ′ nucleotidase/CD73 Mediates Leishmania amazonensis Survival in Macrophages. BioMed Research International, 2022, 2022, 1-10.	1.9	1
2	ENTPDases from Pathogenic Trypanosomatids and Purinergic Signaling: Shedding Light towards Biotechnological Applications. Current Topics in Medicinal Chemistry, 2021, 21, 213-226.	2.1	7
3	Clustering of adenosine A _{2B} receptors with ectonucleotidases in caveolinâ€rich lipid rafts underlies immunomodulation by <i>Leishmania amazonensis</i> . FASEB Journal, 2021, 35, e21509.	0.5	5
4	Ectonucleotidases from trypomastigotes from different sources and various genetic backgrounds of Trypanosoma cruzi potentiate their infectivity and host inflammation. Cytokine, 2020, 136, 155255.	3.2	4
5	The Schistosomiasis SpleenOME: Unveiling the Proteomic Landscape of Splenomegaly Using Label-Free Mass Spectrometry. Frontiers in Immunology, 2018, 9, 3137.	4.8	8
6	New Lager Brewery Strains Obtained by Crossing Techniques Using <i>Cachaça</i> (Brazilian Spirit) Yeasts. Applied and Environmental Microbiology, 2017, 83, .	3.1	14
7	Leishmania amazonensis-Induced cAMP Triggered by Adenosine A2B Receptor Is Important to Inhibit Dendritic Cell Activation and Evade Immune Response in Infected Mice. Frontiers in Immunology, 2017, 8, 849.	4.8	24
8	Purinergic signaling and infection by Leishmania : A new approach to evasion of the immune response. Biomedical Journal, 2016, 39, 244-250.	3.1	30
9	Tailored antihypertensive drug therapy prescribed to older women attenuates circulating levels of interleukin-6 and tumor necrosis factor-α. Clinical Interventions in Aging, 2015, 10, 209.	2.9	4
10	The Antileishmanial Potential of C-3 Functionalized Isobenzofuranones against Leishmania (Leishmania) Infantum Chagasi. Molecules, 2015, 20, 22435-22444.	3.8	9
11	E-NTPDase (ecto-nucleoside triphosphate diphosphohydrolase) of Leishmania amazonensis inhibits macrophage activation. Microbes and Infection, 2015, 17, 295-303.	1.9	24
12	Nanoemulsions loaded with amphotericin B: A new approach for the treatment of leishmaniasis. European Journal of Pharmaceutical Sciences, 2015, 70, 125-131.	4.0	58
13	Leishmania infantum Ecto-Nucleoside Triphosphate Diphosphohydrolase-2 is an Apyrase Involved in Macrophage Infection and Expressed in Infected Dogs. PLoS Neglected Tropical Diseases, 2014, 8, e3309.	3.0	22
14	Short-term protection conferred by Leishvacin® against experimental Leishmania amazonensis infection in C57BL/6 mice. Parasitology International, 2014, 63, 826-834.	1.3	12
15	The endogenous cytokine profile and nerve fibre density in mouse ear Leishmania major-induced lesions related to nociceptive thresholds. Experimental Parasitology, 2013, 133, 193-200.	1.2	10
16	Leishmania Metacyclogenesis Is Promoted in the Absence of Purines. PLoS Neglected Tropical Diseases, 2012, 6, e1833.	3.0	42
17	Ecto-Nucleotidase Activities of Promastigotes from Leishmania (Viannia) braziliensis Relates to Parasite Infectivity and Disease Clinical Outcome. PLoS Neglected Tropical Diseases, 2012, 6, e1850.	3.0	35
18	<i>Leishmania amazonensis</i> impairs <scp>DC</scp> function by inhibiting <scp>CD</scp> 40 expression via <scp>A</scp> _{2B} adenosine receptor activation. European Journal of Immunology, 2012, 42, 1203-1215.	2.9	40

#	Article	IF	CITATIONS
19	Low and high-dose intradermal infection with Leishmania majorand Leishmania amazonensis in C57BL/6 mice. Memorias Do Instituto Oswaldo Cruz, 2010, 105, 736-745.	1.6	29
20	Antigenic extracts of Leishmania braziliensis and Leishmania amazonensis associated with saponin partially protects BALB/c mice against Leishmania chagasi infection by suppressing IL-10 and IL-4 production. Memorias Do Instituto Oswaldo Cruz, 2010, 105, 818-822.	1.6	22
21	The influence of ecto-nucleotidases on Leishmania amazonensis infection and immune response in C57B/6 mice. Acta Tropica, 2010, 115, 262-269.	2.0	60
22	Histopathology of Leishmania major infection: revisiting L. major histopathology in the ear dermis infection model. Memorias Do Instituto Oswaldo Cruz, 2009, 104, 918-922.	1.6	22
23	Immune response of bovines stimulated by synthetic vaccine SBm7462® against Rhipicephalus (Boophilus) microplus. Veterinary Parasitology, 2009, 166, 333-339.	1.8	17
24	Development of chronic cardiomyopathy in canine Chagas disease correlates with high IFN-Î3, TNF-α, and low IL-10 production during the acute infection phase. Veterinary Immunology and Immunopathology, 2009, 130, 43-52.	1.2	67
25	Extracellular nucleotide metabolism in Leishmania: influence of adenosine in the establishment of infection. Microbes and Infection, 2008, 10, 850-857.	1.9	72
26	Early infection with Leishmania major restrains pathogenic response to Leishmania amazonensis and parasite growth. Acta Tropica, 2008, 106, 27-38.	2.0	9
27	lgG isotype profile is correlated with cardiomegaly in Beagle dogs infected with distinct Trypanosoma cruzi strains. Veterinary Immunology and Immunopathology, 2008, 124, 163-168.	1.2	20
28	Successful vaccination against Leishmania chagasi infection in BALB/c mice with freeze-thawed Leishmania antigen and Corynebacterium parvum. Acta Tropica, 2007, 104, 133-139.	2.0	5
29	Interferon-Î ³ induced nitric oxide mediates in vitro neuronal damage by Trypanosoma cruzi-infected macrophages. Neurobiology of Disease, 2007, 25, 170-178.	4.4	21
30	CD8+T cells are not required for vaccine-induced immunity against Leishmania amazonensis in IL-12/23P40â^'/â^' C57BL/6 mice. Microbes and Infection, 2007, 9, 1124-1134.	1.9	3
31	Lactobacillus delbrueckii as a potential skin adjuvant for induction of type 1 immune responses. Frontiers in Bioscience - Landmark, 2007, 12, 1300.	3.0	7
32	Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40. Immunology Letters, 2006, 105, 38-47.	2.5	15
33	Germ-free mice produce high levels of interferon-gamma in response to infection with Leishmania major but fail to heal lesions. Parasitology, 2005, 131, 477.	1.5	53
34	Trypanosoma cruzi: Influence of predominant bacteria from indigenous digestive microbiota on experimental infection in mice. Experimental Parasitology, 2005, 111, 87-96.	1.2	6
35	Intramuscular immunization with p36(LACK) DNA vaccine induces IFN-Î ³ production but does not protect BALB/c mice against Leishmania chagasi intravenous challenge. Parasitology Research, 2005, 98, 67-74.	1.6	57
36	Involvement of the Chemokine RANTES (CCL5) in Resistance to Experimental Infection with Leishmania major. Infection and Immunity, 2004, 72, 4918-4923.	2.2	41

#	Article	IF	CITATIONS
37	Influence of normal microbiota on some aspects of the immune response during experimental infection with Trypanosoma cruzi in mice. Journal of Medical Microbiology, 2004, 53, 741-748.	1.8	22
38	Immune response induced by New World Leishmania species in C57BL/6 mice. Parasitology Research, 2004, 94, 207-212.	1.6	57
39	Activity of the New Triazole Derivative Albaconazole against Trypanosoma (Schizotrypanum) cruzi in Dog Hosts. Antimicrobial Agents and Chemotherapy, 2004, 48, 4286-4292.	3.2	73
40	Leishmania braziliensis: partial control of experimental infection by interleukin-12 p40 deficient mice. Memorias Do Instituto Oswaldo Cruz, 2004, 99, 289-294.	1.6	30
41	Screening of expression libraries using ELISA: identification of immunogenic proteins from Tityus bahiensis and Tityus serrulatus venom. Toxicon, 2001, 39, 679-685.	1.6	22
42	Purification, amino-acid sequence and partial characterization of two toxins with anti-insect activity from the venom of the South American scorpion Tityus bahiensis (Buthidae). Toxicon, 2001, 39, 1009-1019.	1.6	40
43	Immunochemotherapy in American cutaneous leishmaniasis: immunological aspects before and after treatment. Memorias Do Instituto Oswaldo Cruz, 2001, 96, 89-98.	1.6	51
44	Coinfection with <i>Toxoplasma gondii</i> Inhibits Antigen-Specific Th2 Immune Responses, Tissue Inflammation, and Parasitism in BALB/c Mice Infected with <i>Leishmania major</i> . Infection and Immunity, 1999, 67, 4939-4944.	2.2	33
45	Vaccine for prophylaxis and immunotherapy, Brazil. Clinics in Dermatology, 1996, 14, 503-512.	1.6	57
46	Switch from a type 2 to a type 1 T helper cell response and cure of established Leishmania major infection in mice is induced by combined therapy with interleukin 12 and Pentostam Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 3142-3146.	7.1	180
47	The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science, 1994, 263, 235-237.	12.6	739
48	Infection with Leishmania major induces interleukin-12 production in vivo. Immunology Letters, 1994, 40, 157-161.	2.5	87
49	Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infection and Immunity, 1993, 61, 2952-2959.	2.2	273
50	Evidence for the occurrence of LDL receptors in extracts of schistosomula of Schistosoma mansoni. Molecular and Biochemical Parasitology, 1988, 28, 145-152.	1.1	50